PAA
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Pharmaust Limited
🇦🇺 ASX
📦 LOGISTICS
📈 HIGH PRICE GROWTH
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 15.38%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
20
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
PharmAust Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-10-05. The Company’s segments include Corporate and Research. The firm is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The firm's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The firm is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. The company is focused on starting Phase II/III clinical study of MPL. The company has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. The company is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.
📈 Performance
Price History
+2434.99%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.23
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PAA
0
📊 Total Capital Earnings
$53K
🔃 Average investment frequency
29 weeks
💵 Average investment amount
$1,711
⏰ Last time a customer invested in PAA
71 days
PAA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in PAA also invest in...
🙌 Performance (5Yr p.a)
11.43%
📊 Share price
$0.17 AUD
📈 HIGH PRICE GROWTH
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
🙌 Performance (5Yr p.a)
12.87%
📊 Share price
$16.09 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
⛳️ DIVERSIFIED
Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.
🙌 Performance (5Yr p.a)
68.37%
📊 Share price
$0.38 AUD
📦 LOGISTICS
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
14.07%
📊 Share price
$140.20 AUD
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
🌏 GLOBAL
🤖 TECHNOLOGY
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
4.12%
📊 Share price
$137.57 AUD
⛳️ DIVERSIFIED
💸 FINANCIALS
🇦🇺 AUSTRALIA